According to filings with the U.S. Securities and Exchange Commission, Solve Therapeutics, Inc. is raising up to $120,535,618.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Solve Therapeutics, Inc.
Our teams approach to ADCs is grounded in a deep understanding of how each component of the molecule antibody, linker, and payload can be optimized to work synergistically and meaningfully improve the benefitrisk profile for patients. While ADCs have demonstrated substantial clinical value, challenges remain, including off-target toxicity, suboptimal payload delivery, and limitations in patient selection. Our technologies are engineered to address these issues through advanced antibody design, a novel hydrophilic and highly stable linker system (CloakLink), and an integrated diagnostic platform that helps identify patients most likely to benefit from treatment. Because the cytotoxins used as ADC payloads are typically highly hydrophobic, many ADCs suffer from poor plasma stability and suboptimal pharmacokinetics factors that can compromise both safety and efficacy. To address these limitations, Solve developed CloakLink, a hydrophilic cleavable linker system. CloakLink is engineered to mask the hydrophobic properties of ADC payloads, enabling enhanced plasma stability, improved pharmacokinetics, reduced toxicity, and potent tumor cell killing. The result is a class of ADCs with higher therapeutic indices and improved overall performance. Beyond increased hydrophilicity, the exceptional stability of our ADCs also stems from key structural features of CloakLink, including the strategic placement of a peptide-based release trigger. This design confers resistance to off-target cleavage and offers functional advantages over earlier-generation linker technologies. CloakLink is compatible with a wide range of payloads, drug-antibody ratios (DARs), and targeting antibodies.

To learn more about Solve Therapeutics, Inc., visit https://solvetx.com/
Solve Therapeutics, Inc. Linkedin Page: https://www.linkedin.com/company/solve-therapeutics-inc/

Contact:
David Johnson, Chief Executive Officer
858-357-4137

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.